Innoviva Net Worth 2010-2025 | INVA

Interactive chart of historical net worth (market cap) for Innoviva (INVA) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Innoviva net worth as of June 20, 2025 is $1.32B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.318B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $722.866B 55.43
Johnson & Johnson (JNJ) United States $360.406B 14.90
AbbVie (ABBV) United States $327.315B 18.04
Roche Holding AG (RHHBY) Switzerland $250.015B 0.00
Novartis AG (NVS) Switzerland $244.555B 13.97
Merck (MRK) United States $198.522B 10.15
Pfizer (PFE) United States $136.278B 7.47
Sanofi (SNY) France $117.375B 11.56
Bayer (BAYRY) Germany $30.180B 6.14
Novo Nordisk (NVO) Denmark $0.000B 21.83